A Miracle of Biblical Proportions

Forward to a Friend Having trouble viewing this issue? Click here. Refer a Friend to Energy and Capital.

A Miracle of Biblical Proportions By Jason Stutman | Monday, May 12th, 2014 At two years of age, the average child has a vocabulary of about 100 words. By two and a half, they will know close to 300 — and will likely be talking nonstop. This sudden acquisition of new words is what experts call the “naming explosion.” And despite the common complaint from parents during this time that they can never seem to get a moment of peace, it's something to remain incredibly appreciative of. The fact is, if your child isn't able to spit out this many words by age three, chances are high there's an underlying medical issue at hand. Take Alex Denworth, for example. At 20 months, Alex could speak only four words: "Mama," "Dada," "hello," and "up." At first glance, this may have seemed like an issue of intelligence. But Alex wasn't mentally disabled by any means. In fact, he was fully engaged and competent with his toy trucks, building blocks, and just about every other typical toddler activity you could think of. The medical issue Alex was suffering from actually had nothing to do with his mental wit, but was rather an issue of hearing: Alex suffered from a deformity in his inner ear known as Mondini dysplasia alongside a separate and progressive condition, Enlarged Vestibular Aqueduct. In short, this meant Alex was profoundly deaf in his right ear and moderately deaf in the left. More alarmingly, it meant that a simple bump on the head or sudden change in pressure would cause even further hearing loss. To the dismay of his parents, Alex couldn't ride on a plane, swim, or even step into an elevator without the risk of going completely deaf. Advertisement This emerging technology just handed early investors over 4,985%... and it's getting ready to do it again At this very moment, an emerging technology is taking the world by storm, changing lives, and making early investors rich. In fact, one stock just soared from $10 to $500, handing savvy investors a whopping 5,000%. That's good enough to turn a $25,000 investment into $1.25 million. The best part? This is only the tip of the iceberg. In fact, in the following video, I'll show you three stocks that have absolutely explosive upside potential and the ability to turn every $1 you invest into $5... $10... even $15 or more. Click here now to learn about these three stocks. “A Miracle of Biblical Proportions” Upon being diagnosed, Alex immediately became a candidate for a cochlear implant, a small but complex electronic device that provides direct stimulation to the auditory nerves of a patient's inner ear. Unlike standard hearing aids, which only amplify sound, cochlear implants turn sound waves into electrical waves the brain can interpret. Cochlear implants in their crudest form have been around since the 1960s, but it was only recently that they became precise enough for patients to identify individual words or even enjoy the sounds of music. Today, these implants are advanced enough to completely change a patient's way of life. In the case of Alex Denworth, the procedure was described by his father as “a miracle of biblical proportions.” And if those words are not enough, here's an image of a child hearing for the very first time: If that's not absolutely precious, I'm not quite sure what is. Still, cochlear implants are by no means perfect. While it's enough to make most patients completely elated, what's actually heard is largely distorted — regular speech ends up sounding something like the Dalek robots from Dr. Who. Advertisement You Made a Big Mistake. Here’s How to Fix It... Over the last 7 months, I've been making the call on a small biotech company with a patented cancer-curing liquid that will soon hit the market. But you missed out. Those who followed my call made 300% returns in 7 months. On the heels of major news concerning this company, I am making a final push for you to get in now while this company still trades under $3 a share. But there isn't much time left. Either you get in now, or miss out again. Go here now to buy this stock. Putting the 'Bio' in Biotech If the above reference isn't familiar, neuroscientist Gary Housley puts the issue into clear, scientific terms: “Cochlear implants are very effective for picking up speech, but they struggle to reproduce pitch, spectral range, and dynamics.” To tackle this hurdle, researchers are finding new and exciting ways to regrow the natural mechanisms of the inner ear. In particular, Housley and fellow researchers are currently investigating the use of cochlear implants for gene therapy. The group has recently made a breakthrough by demonstrating how to successfully regenerate auditory nerves using a combination of electrode stimulation and gene vectors. Without getting too technical, Housley and company were able to regenerate nerves and show a better response to sound in guinea pigs, an animal with both a similar cochlea size and structure to humans. Ultimately, the study suggests the ability to use cochlear implants to naturally improve the hearing of human patients in the near future and quite possibly bring about a cure for deafness. Perhaps even more exciting is the fact that the world's first human gene therapy trial will take place just two months from now. The trial, led by Kansas Medical Center's Hinrich Staecker, takes a more conventional approach than Housley's electrode stimulation method, using a harmless virus to deliver gene therapy. In Staecker's own words: "The holy grail is to give people natural hearing back. That's what we hope to do — we are essentially repairing the ear rather than artificially imitating what it does." The trials follow successful results from last year when Staecker's team was able to use the same virus to deliver a gene called Atoh1 to improve the hearing of mice by 20 decibels. That's about the difference between cupping your hands over your ears and then taking them off again. Incredibly enough, deafness is just the tip of the iceberg when it comes to regenerative medicine. At this very moment, there are several small companies we're aware of working with similar methods to cure blindness and even regrow tissue damaged from heart attacks. More on that in just a few weeks. Turning progress to profits,    Jason Stutman  @JasonStutman on Twitter Energy and Capital's tech expert, Jason Stutman has worked as an educator in mathematics, technology, and science... Before joining the Energy and Capital team, Jason served on multiple technology development committees, writing and earning grants in educational and behavioral technologies. Jason offers readers keen insights on prominent tech trends while exposing otherwise unnoticed opportunities. I liked this article | I did not like this article Follow Energy and Capital on The Bottom Line Related Articles Investing in Alternative THC Delivery What Bioprinting Means for the Future of Medicine Investing in Agricultural Biotech Recently... Smart Money Goes Where? Time to Buy Hydro? Eagle Ford Profits Orbital Sciences (NASDAQ: ORB) to Merge with Alliant Techsystems (NASDAQ: ATK) One Thing Every Investor Must Have

This email was sent to ignoble.experiment@arconati.us . You can manage your subscription and get our privacy policy here. Energy and Capital, Copyright © 2014, Angel Publishing LLC, 111 Market Place #720, Baltimore, MD 21202. All rights reserved. No statement or expression of opinion, or any other matter herein, directly or indirectly, is an offer or the solicitation of an offer to buy or sell the securities or financial instruments mentioned. While we believe the sources of information to be reliable, we in no way represent or guarantee the accuracy of the statements made herein. Energy and Capital does not provide individual investment counseling, act as an investment advisor, or individually advocate the purchase or sale of any security or investment. Neither the publisher nor the editors are registered investment advisors. Subscribers should not view this publication as offering personalized legal or investment counseling. Investments recommended in this publication should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company in question. Unauthorized reproduction of this newsletter or its contents by Xerography, facsimile, or any other means is illegal and punishable by law. Please note: It is not our intention to send email to anyone who doesn't want it. If you're not sure why you're getting this e-letter, or no longer wish to receive it, get more info here, including our privacy policy and information on how to manage your subscription.